相关实验视频
Updated: Jun 27, 2025
09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
18.4K
在阿尔茨海默氏病的粉样蛋白时间表上,特征性脑和认知衰退
Karly A Cody1,2, Rebecca E Langhough1,2,3, Matthew D Zammit1,4,5
1Wisconsin Alzheimer's Disease Research Center, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792, USA.
Brain : a journal of neurology
|April 26, 2024
概括
这项研究将粉样蛋白阳性开始与陶传播和阿尔茨海默病的认知衰退联系起来. 较长的粉样蛋白持续时间与增加的病理和较高的认知障碍风险相关.
科学领域:
- 神经科学是一个神经科学.
- 医疗成像医学成像
- 阿尔茨海默氏症疾病研究研究
背景情况:
- 纵向PET成像可以估计个体粉样蛋白异常发作.
- 了解粉样蛋白,蛋白和认知衰退之间的时间关系对于阿尔茨海默病 (AD) 的进展至关重要.
- 现有的研究缺乏一个时间框架来将粉样蛋白的发病与下游的病理和临床变化联系起来.
研究的目的:
- 将粉样蛋白水平重新置于时间领域,以了解下游的阿尔茨海默病过程.
- 调查tau神经纤维状 (NFT) 积累和相对于粉样蛋白阳性开始的认知衰退的时空模式.
- 为阿尔茨海默病的进展建立一个时间疾病背景.
主要方法:
- 包括来自威斯康星州阿尔茨海默氏症预防登记处和ADRC的601名个人 (认知正常,轻度认知障碍,痴呆症).
- 使用粉样蛋白 (11C-匹兹堡化合物B) 和 (18F-MK-6240) 的PET成像,以及纵向的神经心理评估.
- 估计的粉样蛋白阳性 (A+) 发病年龄和粉样蛋白慢性 (A+持续时间的年份) 来分析tau PET负担和认知衰退.
主要成果:
- 每十年的A+持续时间都与tau传播的空间范围增加相关,反映了NFT早期到晚期的阶段.
- 脑内皮层的负担在A+发病后10年内可检测,对早期的粉样蛋白病理和损伤最敏感.
- 在没有认知障碍的个体中,A+持续时间和内分泌协同增加了认知能力下降的可能性.
结论:
- 粉样质时间框架提供了跨AD连续性的tau沉积的时空特征.
- 粉样蛋白持续时间显著解释了tau传播大小和地形的变异性,重复了神经病理NFT分期.
- 将疾病进展与粉样蛋白发作联系在一起,提供了一个时间上下文,以告知AD预后和治疗时间.
相关概念视频
01:26Alzheimer's Disease: Overview
468
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
468
01:22Alzheimer's Disease: Treatment
183
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
183
01:30Dementia
113
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
113
01:30Cognitive Development During Adulthood
94
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
94
03:03Amyloid Fibrils
9.5K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.5K
01:13Amnesia
123
Amnesia is a condition marked by long-term memory loss, which impairs the ability to recall past events or create new memories.
The severity and duration of memory loss vary depending on the type and underlying cause. Amnesia is classified into two main types: retrograde and anterograde.
Retrograde amnesia is marked by the loss of memories formed before the onset of the condition. Patients may recall distant past events but often forget those occurring shortly before the incident.
Anterograde...
The severity and duration of memory loss vary depending on the type and underlying cause. Amnesia is classified into two main types: retrograde and anterograde.
Retrograde amnesia is marked by the loss of memories formed before the onset of the condition. Patients may recall distant past events but often forget those occurring shortly before the incident.
Anterograde...
123